Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received previous treatment, the drugmaker said on Wednesday.

Dapagliflozin, a SGLT2 inhibitor used for type 2 diabetes, alleviates steatohepatitis and fibrosis in patients with ...

People who take weight-loss drugs hoping to achieve the impressive results observed in large clinical trials may need to ...

Despite incomplete evidence, longevity enthusiasts are experimenting with SGLT2 inhibitors in their quest to live healthier ...

Everyday human behavior is guided and shaped by the search for rewards. This includes eating tasty meals, drinking something ...

Reward memories both help people survive and lead to substance use disorders. Delving into the intricate mechanisms of how the brain remembers rewards at the cellular and genetic levels can help ...

Raiders wide receiver Jakobi Meyers would speak humorously about Pete Carroll's energy, saying that he has to be on "some ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

India has officially approved and launched Mounjaro (tirzepatide), a groundbreaking injectable medication for the treatment of Type 2 diabetes and obesity. Developed by Eli Lilly and Company, the drug ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Semaglutides, which are used to treat type 2 diabetes and obesity, were the most-sold medication in Finland last year, ...